Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Last Updated: August 19, 2022

Investigational Drug Information for AZD-1236

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

What is the drug development status for AZD-1236?

AZD-1236 is an investigational drug.

There have been 32 clinical trials for AZD-1236. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1^st 2007.

The most common disease conditions in clinical trials are Lung Neoplasms, Small Cell Lung Carcinoma, and Adenocarcinoma. The leading clinical trial sponsors are AstraZeneca, Samsung Medical Center, and National Cancer Institute (NCI).

Summary for AZD-1236

US Patents	0
International Patents	0
US Patent Applications	12
WIPO Patent Applications	6
Japanese Patent Applications	4
Clinical Trial Progress	Phase 2 (2007-12-01)
Vendors	20

Recent Clinical Trials for AZD-1236

Title	Sponsor	Phase
Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects	AstraZeneca	Phase 2
Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects	Samsung Medical Center	Phase 2
Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	National Cancer Institute (NCI)	Phase 2

See all AZD-1236 clinical trials

Clinical Trial Summary for AZD-1236

Top disease conditions for AZD-1236

Top clinical trial sponsors for AZD-1236

See all AZD-1236 clinical trials

US Patents for AZD-1236

+ Get email alerts for changes to this table

Subscribe to access the full database, or Try it Free
Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
>Drugname	>Patent Number	>Patent Title	>Patent Assignee	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Dow

Mallinckrodt

Express Scripts

Colorcon

Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.